BioSpace News Archive

On March 5 , U.S. House and Senate lawmakers introduced the VALID Act, which would give the Food and Drug Administration (FDA) new, expansive powers to regulate laboratory developed tests—tests that are already regulated by the Centers for Medicare and Medicaid Services (CMS) and are subject to stringent personnel, quality control, and

Two poster sessions were highlighted at the Cutting Edge of Transplantation summit 2020. Balancing equity and utility in the face of an organ shortage

A recent research report on Global Anaesthesia Machine Market 2020 deeply studied great features of the industry.

Digirad Corporation reported its financial results for the fourth quarter and year ended December 31, 2019.

Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced its financial results for the full year ended December 31, 2019

As innovations in cancer screening through diagnostic imaging continue to help clinicians accurately detect and diagnose, challenges to the ability to share large file sizes has increased.

Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early stage breast cancer, announced today the presentation of multiple posters at the 37th Annual Miami Breast Cancer Conference

A timeline clearly recorded how China has taken the initiative to fulfill its international responsibilities and unite with the global society to fight against Covid-19.

Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 5:00 PM EDT on March 10, 2020, to discuss its fourth quarter results and progress in its clinical programs.

WIRB-Copernicus IRB will give priority to the institutional review board (IRB) review of potentially life-saving COVID-19 vaccines and medications and waive their initial protocol review fees